-
SILVER SPRING, Maryland The cost of developing a drug-eluting stent (DES) has been pegged as somewhere north of $100 million, but that number has not deterred several device makers from wading into this end of the cardiovascular device pool.
-
In light of recent news that blood substitutes have led to a 30% increase in the risk of death and a nearly threefold chance of having a heart attack, Synthetic Blood International (SBI; Costa Mesa, California) has attempted to distance itself from the "blood substitute" sector.
-
A treatment protocol and a communitywide task force are among the initiatives Harris Methodist Southwest Hospital in Fort Worth, TX, has initiated to help adults with sickle cell disease learn to manage their condition and limit their visits to the hospital.
-
When MCGHealth was planning a new neuroscience unit at its Augusta, GA, facility, patients and family members were involved every step of the way.
-
Including patients and family members in everything from developing a plan of care to making changes in the hospital's physical appearance has paid off at MCGHealth in Augusta, GA.
-
-
Haissaguerre and his colleagues from twenty-two world-wide arrhythmia referral centers collected 206 patients with idiopathic ventricular fibrillation.
-
Elevated troponin I is a nonspecific finding, but suggests a poor prognosis regardless of its cause. These investigators from Israel sought to clarify these observations.
-
-
Shingles vaccine added to CDC list of vaccines for adults 60 and older; CDC recommends Tdap for postpartum women; new study suggests sequential therapy with antibiotics for H. pylori may be more effective than standard therapy; FDA Actions.